Skip to main content
SpringerLink
Log in

Two mast cell stabilizers, pemirolast potassium 0.1% and nedocromil sodium 2%, in the treatment of seasonal allergic conjunctivitis: A comparative study

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

This randomized, double-masked, active-control, parallel-group trial compared the mast cell stabilizers pemirolast potassium 0.1% and nedocromil sodium 2% in the treatment of seasonal allergic conjunctivitis. Pemirolast is currently indicated for four-times-daily administration, nedocromil, for twice-daily dosing. Both ophthalmic solutions were instilled bilaterally twice a day for 8 weeks. The study involved four office visits and two telephone contacts. Participants evaluated their symptoms daily in take-home diaries (itching was the primary efficacy variable) and completed questionnaires to assess comfort. Of a total enrollment of 80, 78 patients completed the study. No significant differences were found between pemirolast and nedocromil on any signs or symptoms of allergic conjunctivitis (redness, chemosis, itching, eyelid swelling). At each visit, pemirolast was rated significantly more comfortable than nedocromil. A significantly higher percentage of the pemirolast group experienced no signs or symptoms at work or school (58% vs 28%; P = .005). The number of adverse events did not differ significantly between groups. Twice-daily administration of pemirolast potassium was as efficacious and safe as twice-daily nedocromil sodium in the 8-week treatment of ragweed allergic conjunctivitis and was superior to nedocromil in comfort. Increased comfort with pemirolast may increase patient satisfaction and compliance with therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abelson MB, Chapin MJ. Current and future topical treatments for ocular allergy.Compr Ophthalmol. 2000;1:303–320.

    Google Scholar 

  2. Allansmith MR, Ross RN. Ocular allergy.Clin Allergy. 1988;18:1–13.

    Article  PubMed  CAS  Google Scholar 

  3. Kinet JP. The high-affinity receptor for immunoglobulin-E: structure, function, and role in allergy. In: Gallin JI, Goldstein IM, Snyderman R, eds.Inflammation: Basic Principles and Clinical Correlates. 2nd ed. New York: Raven Press; 1992:702–705.

    Google Scholar 

  4. Allansmith MR. Immunology of the eye. In: Allansmith MR, ed.The Eye and Immunology. St. Louis, Mo: CV Mosby; 1982:99–115.

    Google Scholar 

  5. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis.Clin Exp Allergy. 1991;21:77–83.

    Article  PubMed  CAS  Google Scholar 

  6. Juniper EF. Rhinitis management: the subject’s perspective.Clin Exp Allergy. 1998;28(suppl 6): 34–38.

    Article  PubMed  Google Scholar 

  7. Berdy GJ, Abelson MB. Antihistamines and mast cell stabilizers in allergic ocular disease. In: Albert DM, Jakobiec FA, eds.Principles and Practice of Ophthalmology. Philadelphia: WB Saunders; 1994:1028–1042.

    Google Scholar 

  8. Norris AA, Holgate ST. Cromolyn sodium and nedocromil sodium. In: Middleton E, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW, eds.Allergy. Principles and Practice. Boston: CV Mosby; 1998:661–667.

    Google Scholar 

  9. Kjellman MN-I, Stevens MT. Clinical experience with Tilavist: an overview of efficacy and safety.Allergy. 1995;50(suppl 21):14–22.

    Article  PubMed  CAS  Google Scholar 

  10. El Hennawi M. A double-blind placebo controlled group comparative study of ophthalmic sodium cromoglycate and nedocromil sodium in the treatment of vernal keratoconjunctivitis.Br J Ophthalmol. 1994;78:365–369.

    Article  PubMed  Google Scholar 

  11. Alexander M. Comparative therapeutic studies with Tilavist.Allergy. 1995;50(suppl 21):23–29.

    Article  PubMed  CAS  Google Scholar 

  12. Van Bijsterveld OP, Moons L, Verdonck M, et al. Nedocromil sodium treats symptoms of perennial allergic conjunctivitis not fully controlled by sodium cromoglycate. A double-masked placebo controlled group comparative study.Ocular Immunol Inflamm. 1994;2:177–186.

    Article  Google Scholar 

  13. Fujimiya H, Nakashimia S, Miyata H, Nozawa Y. Effect of a novel antiallergic drug, pemirolast, on activation of rat peritoneal mast cells: inhibition of exocytotic responses and membrane phospholipid turnover.Int Arch Allergy Appl Immunol. 1991;96:62–67.

    PubMed  CAS  Google Scholar 

  14. Abelson MB. Comparison of the conjunctival allergen challenge with the environmental model of allergic conjunctivitis.Acta Ophthalmol Scand. 1999;77(suppl 228):38–42.

    Google Scholar 

  15. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis.Arch Ophthalmol. 1990;108:84–88.

    PubMed  CAS  Google Scholar 

  16. Nelson P, Aspinall P, Papasouliotis O, Worton B, O’Brien C. Quality of life in glaucoma and its relationship with visual function.J Glaucoma. 2003;12:139–150.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, University of Texas Health Science Center Audie Murphy Veterans’ Administration Hospital, San Antonio, Texas

    David G. Shulman MD

Authors
  1. David G. Shulman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shulman, D.G. Two mast cell stabilizers, pemirolast potassium 0.1% and nedocromil sodium 2%, in the treatment of seasonal allergic conjunctivitis: A comparative study. Adv Therapy 20, 31–40 (2003). https://doi.org/10.1007/BF02850117

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02850117

Keywords

Search

Navigation